Company intelligence / Profile preview

ImmuneSpec

Ownership: Private
Development stage: Commercial

Overview

ImmuneSpec offers advanced immunopeptidomics services using a proprietary mass spectrometry workflow to identify and characterize MHC-presented peptides. Their technology enables rapid, high-throughput identification of tumor neoantigens, pathogen-derived antigens, and assessment of unwanted immunogenicity in biotherapeutic candidates. This supports rational design of vaccines and safer biologic drugs. They have been recognized with industry awards for excellence in biotechnology service provision

Therapeutic areas: OncologyImmunologyInfectious Diseases
Modalities: PeptidesProteinBiologic
Industry: Drug Discovery Services

Partnerships

Institute of Tropical Medicine AntwerpInstitut Curie

Beyond the preview

Go deeper on ImmuneSpec.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ImmuneSpec.

Explore the full profile